exhibited an oral bioavailability of 12.4% in rats and showed no overt toxicity in acute or chronic studies. These findings provide promising preclinical candidates for a new generation of NSAIDs and introduce a novel molecular scaffold for future COX inhibitor design.
Li et al. (Thu,) studied this question.